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Background: Xuesaitong Injection (XST) is one of the most commonly used medicines for treating acute cerebral
infarction (ACI) in China. However, compared to the conventional therapy with western medicines (WM), the
effectiveness and safety of XST as an adjuvant treatment for ACI needs to be systematically reviewed.
Methods: Randomized controlled trials (RCTs) comparing XST & WM with WM for treating ACI were included. Two
reviewers independently extracted data. The Cochrane table of Risk of Bias was used to assess the quality of the
included studies, and a meta-analysis was conducted using Review Manager 5.2.
Results: 23 RCTs, involving 2196 participants, were included in this study. Methodological quality was not well. The
meta-analysis indicated that compared to WM, the combined use of XST and WM was more effective in terms of
the total clinical effective rate [RR = 1.21, 95% CI (1.16, 1.25), P < 0.00001], neurological deficit scores [MD = −3.31,
95% CI (−4.10, −2.52), P < 0.00001], and plasma viscosity [MD = −0.13, 95% CI (−0.15, −0.11), P < 0.00001]. The
included studies reported 37 adverse events, 17 of which belonged to experimental groups.
Conclusion: XST combined with WM appeared to be effective for ACI. However, the evidence of XST for treating
ACI should be carefully interpreted due to the small sample size, limited number of trials, and unsatisfactory quality
of research.
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Acute cerebral infarction (ACI) is one of the most com-
monly seen cerebral vascular diseases, which accounting
for about 70% of stroke [1]. The incidence, mortality and
recurrence rate of ACI are both high, usually leads to
serious damage of central nervous system [2]. ACI refers
to the process that artery stenosis or blockage causing
brain tissue hypoxic ischemia, and then resulting in
brain dysfunction [3]. Currently, the conventional ther-
apy with western medicines (WM) mainly includes
thrombolysis, improving microcirculation, restoring
blood supply to ischemic area, using cerebral protection
agents, controlling cerebral edema, preventing and treating
complications, controlling hypertension, reducing blood
viscosity, and so on [1,2].* Correspondence: exogamy@163.com; zhangbing6@263.com
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unless otherwise stated.Some scholars hold the opinion that in traditional
Chinese medicine (TCM), the pathogenesis of ACI is due
to the disorder of Qi and blood, and then cerebral veins
blocking, brain cells ischemia and hypoxia [4]. Therefore,
the treatment of promoting blood flow is the first choice.
There are numbers of literatures reported that Chinese
medicinal herbs have unique advantages in the treatment
of ACI by removing stasis. Xuesaitong Injection (XST), as
one of the most commonly used medicines for treating
ACI in China. Its active ingredient is attributed to extract
from the roots of Pannax notoginseng (Sanqi), which
mainly contains tetracyclic triterpenoid saponins, generally
called as “Panax notoginseng saponins” (PNS). PNS has
good therapeutic effects on cardiovascular and cerebrovas-
cular system, blood system, and nervous system. Some
pharmacological studies also showed that XST can reduce
the edema caused by cerebral ischemia, protect vascular
endothelial cells, inhibit the adhesion and aggregation ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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radicals, and so on [5-9], which are all beneficial for treat-
ing acute stroke [10].
There were two systematic reviews regarding XST in the
treatment of cerebral infarction [11,12], both showing the
superiority of XST to control group, their delimiting of
acute stage, unreasonable merging of intervention mea-
sures, and low quality of literatures still being controver-
sial. Accordingly, in this systematic review, we chose the
published, qualified and well homogeneity clinical studies
regarding the combined use of XST for treating ACI to
make meta-analysis, hopefully to provide more reliable
evidence for XST’s clinical application.Methods
Inclusion criteria
(1) Study type: clinical randomized controlled trials (RCTs)
using XST as the adjuvant treatment of ACI, regardless of
blinding. (2) Participants: The diagnostic criterion in terms
of TCM was “Apoplexy diagnostic efficacy assessment stan-
dards”; that used in terms of WM was “various types of
cerebrovascular disease diagnostic points”, as determined
after 1995 [13]. Diagnoses were validated using computed
tomography or magnetic resonance imaging scanning.
The course of disease was in 3 days or shorter, and all par-
ticipants were experiencing the first onset of ACI, no limits
on age, gender, race or severity of disease. (3) Interventions:
RCTs comparing combined therapy of XST and conven-
tional treatments versus conventional treatments alone
were included. Conventional treatments included thrombo-
lytic therapy, cerebral protection agents, and so on. The
drugs could be Dextran-40, Mannitol, Aspirin, Citicoline,
Venoruton, Defibrase, Sodium ozagrel, et al. As long as the
conventional treatments were the same between study
groups in one RCT, the RCT could be included. No
limitation on the dosages and treatment courses. (4)
Outcomes: Our primary outcome measure was the total
clinical effective rate, using the following formula: total
clinical effective rate (%) = (number of recovered pa-
tients + number of patients with significant progress +
number of patients with progress) / total number ×
100%. Efficacy criteria predominantly referred to the reduc-
tion of neurological deficit score. Recovered was determined
when the neurological deficit score decreased from 91% to
100%. Significant progress was determined when the
neurological deficit score decreased by between 46%
and 90%. Progress was determined when the neuro-
logical deficit score decreased by between 18% and
45%. No change or worsen was determined when the
functional deficit score decreased by <17%. As second-
ary outcomes, we compared neurological deficit score,
hemorheology value, and number of adverse drug reac-
tions (ADR)/adverse events (AE).Exclusion criteria
If involved any condition of the followings, trials can
be ruled out: data was incorrect, incomplete or not
available; patients with severe cognitive disorder, or
hemorrhagic tendency, or serious complications, such
as atrial fibrillation, severe heart failure, severe liver
and kidney diseases; undergoing surgery, acupuncture
or other physical therapy; combined with any herbal
medicines in experimental or control group during the
treatment.
Searching strategies
The following databases were used for search: the China
National Knowledge Infrastructure Database (CNKI,
980–2014.5), Wan fang Database (1990–2014.5), China
Science and Technology Journal Database (VIP, 1989–
2014.5), Chinese Biomedical Literature Database (CBM,
1981–2014.5), PubMed (1990–2014.5), Embase (1990–
2014.5), and the Cochrane Library (1990–2014.5).
We combined different search strategies as follows: for
English databases, we used free text terms as “Xuesaitong”
and “acute cerebral infarction”; for Chinese databases, we
used subject terms as “Xuesaitong Zhu She Ye” or “Zhu
She Yong Xuesaitong ”or “Xuesaitong Dong Gan Fen
Zhen” or “Luotai”, and then “Que Xue Xing Cu Zhong” or
“Que Xue Xing Zhong Feng” or “Que Xue Xing Nao Xue
Guan Bing” or “Nao Geng Si” or “Nao Geng Se” for
secondary retrieval. No language restriction was used.
Data extraction and quality assessment
Two reviewers (XZ and JW) independently screened
trials. If there was incomplete information in the
study, the reviewer would firstly contact original au-
thors via e-mail or telephone. If no response, the reviewer
would make decision on including or excluding based on
the importance of lack information. XZ and JW inde-
pendently extracted data, including basic information
of patients, interventions, duration of treatment, out-
comes and methodological quality. And the risk of bias
of the included trials was assessed according to the
Cochrane risk of bias tool [14]. It assessed the risk of bias
of random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, selective
reporting, and other biases. Judgments were given for each
item as: low, unclear, and high risk of bias. XZ and JW in-
dependently completed and mutually checked the allo-
cated grades. Any disagreements on data extraction and
quality assessment were resolved by consensus, or if re-
quired by a third reviewer.
Data synthesis
RevMan 5.2 software was used, whose package was
produced and updated by the Nordic Cochrane Centre.
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mean difference (MD) was used for continuous vari-
ables, both with 95% confidence interval (95% CI),
P < 0.05 was considered statistically significant between
experiment and control group. The Chi-square test
was used for checking the heterogeneity between stud-
ies, and I2 was used to show the size of heterogeneity.
If P > 0.1 and I2 < 50%, there was determined to be little
heterogeneity between studies, then we used a fixed ef-
fect model, otherwise we should use a random effect
model. If the number of included trials was sufficient, a
funnel plot would be carried out to assess publication
bias. Sensitivity analysis was performed to inspect the
robustness of the result.Figure 1 Flow chart of literature search.Results
Searching result
Total 1181 articles were retrieved from the databases
listed above. Finally, a total of 23 RCTs were included
[15-37] (Figure 1 flow chart of literature search).
Studies description
The included studies were published between 1999 and
2013. All RCTs originated from China, and were pub-
lished in Chinese. Altogether, 23 RCTs included a total
of 2196 patients. As presented in Table 1, the experi-
mental group consisted of 1141 patients, while the con-
trol group 1055. The included patients were primarily
elderly, the average age of which was about 60.5, with a









Li 1999 [15] 29/33 62.9 ± 7.1 (57 ~ 71) ≤48 31/31 XST 400 mg +WM WM (Defibrase et al.) 14 otal effective rate, changes in cerebral
lood flow and hemorheology
Unclear
Zhang 2002 [16] 52/48 53.0 (37 ~ 70) ≤72 60/40 Luotai 400 mg +WM Xiaoshuanling +WM 14 otal effective rate Unclear
Yuan 2003 [17] 37/25 42 ~ 79 ≤72 32/30 XST 20 ml + WM WM (Piracetam et al.) 15 otal effective rate, changes
n hemorheology
Unclear
Li 2003 [18] 69/27 55.8 (42 ~ 71) ≤72 48/48 XST 400 mg WM (Dextran 40 + citicoline) 15 otal effective rate Unclear
Li 2005 [19] - 48 ~ 73 ≤72 80/76 XST 200 mg +WM WM 20 otal effective rate E 3
He 2006 [20] 48/32 59.3 ± 12.1 (46 ~ 80) ≤72 40/40 XST 10 ml + WM Dextran 40 +WM 14 otal effective rate, neurological
eficit score
None
Wang 2006 [21] 34/21 63.8 (39 ~ 79) ≤24 36/19 XST 600 mg +WM Venoruton +WM 21 otal effective rate None
Yuan 2006 [22] 64/31 63.0 ± 10.4 (46 ~ 74) ≤24 49/46 XST 250 ~ 500 mg +WM WM (Defibrase et al.) 15 otal effective rate E 3
C 7
Zhao 2006 [23] 43/38 60.9 ± 8.1 (45 ~ 70) ≤72 40/41 XST 10 ml + WM WM (Sodium ozagrel +
Defibrase et al.)
14 otal effective rate, changes
n hemorheology
Unclear
Li 2007 [24] 54/36 59.5 ± 13.2 (48 ~ 79) ≤48 45/45 XST 10 ml + WM Dextran 40 +WM 15 otal effective rate None
Wang 2007A [25] 50/26 63.6 (39 ~ 82) ≤24 50/26 XST 600 mg +WM Venoruton +WM 21 otal effective rate None
Wang 2007B [26] - 69.4 (43 ~ 80) ≤72 30/30 XST 20 ml + WM WM (Venoruton et al.) 14 otal effective rate None
Rong 2008 [27] 50/46 59.1 ± 8.4 (39 ~ 77) ≤72 51/45 XST 400 mg +WM Venoruton +WM 14 otal effective rate, neurological
eficit score, Modified Barthel Index,
hanges in hemorheology
None
Zhang 2008 [28] 70/50 56 ± 11 (48 ~ 78) ≤48 65/65 XST 200 ~ 400 mg +WM WM 15 otal effective rate, changes in
emorheology
Unclear
Zi 2008 [29] 49/33 59.5 ± 13.2 (48 ~ 79) ≤48 41/41 XST 10 ml + WM Dextran 40 +WM 15 otal effective rate, neurological
eficit score
None
Duan 2009 [30] 35/34 64.5 ± 8.2 (33 ~ 75) ≤48 36/33 XST 500 mg +WM WM 14 otal effective rate None
Ma 2009 [31] 117/83 65.1 ± 7.0 (45 ~ 85) ≤72 100/100 XST 400 mg +WM Venoruton +WM 15 otal effective rate, neurological
eficit score, changes in
emorheology, glycemia and lipidemia
E 9
C 10
Cai 2011 [32] 42/18 64.2 (47 ~ 86) ≤48 30/30 XST 400 mg +WM WM (Buflomedil hydrochloride +
Low molecular heparin)




Fu 2011 [33] 62/58 55.4 ± 5.1 ≤48 64/58 XST 400 mg +WM WM (Sodium ozagrel et al.) 14 otal effective rate, neurological
eficit score
None





















































Table 1 Characteristics of included trials on XST for ACI (Continued)
Wang 2011 [35] 45/37 55.87 ± 5.23 (42 ~ 76) ≤19 41/41 XST 400 mg +WM WM 21 Total effective rate, Hs-CRP Unclear
Yang 2012 [36] 33/27 57 ± 4 (47 ~ 68) ≤48 30/30 XST 400 mg +WM WM (Sodium ozagrel et al.) 14 Total effective rate C 2
Song 2013 [37] 117/43 62.1 ≤24 80/80 XST 400 mg +WM WM 15 Total effective rate Unclear
NOTE: M: Males; F: Females; E: Experimental group; C: Control group; ADR: Adverse drug reactions; ADE: Adverse drug events; XST: Xuesaitong Injection; WM: Conventional therapy with western medicines, such as
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males. In the experimental group, all the RCTs used XST
combined with the same WM as control group. The daily
dose of XST ranged from 200 ~ 600 mg. In the included
RCTs, XST was produced by Xing Zhong Pharmaceutical
Co., Ltd. in Kunming, Plant Pharmaceutical Co., Ltd. in
Yunnan Province, China, or Zhenbaodao Pharmaceutical
Co., Ltd. in Heilongjiang Province, China. The duration
of treatments ranged from 14 days to 28 days. More de-
tails were shown in Table 1.Quality of the included studies
Three trials used a random number table to generate
random sequence [26,32,34], two grouped according to
the time of admission [21,35], and one grouped accord-
ing to odd and even numbers [24]. And there were two
trials may be used non-random sequence [16,36]. Only
one trail performed single-blinding [18]. Others in the
included trials in this meta-analysis were judged as un-
clear random sequence generation, inadequate allocation
concealment, and inadequate blinding. None of the in-
cluded trials had incomplete outcome data or selective
reporting. Therefore, the quality of the included studies
was not well. More details of the trials were presented in
Figure 2. Funnel plot analysis showed that there was
some significant publication bias in the comparison, as
shown in Figure 3.Effects of interventions
Total clinical effective rate
All the included studies [15-37] reported the total effective
rate. The meta-analysis showed that the effect of XSTcom-
bined with WM was better than WM alone in improving
the total effective rate. The statistical difference between
the two groups was significant [23RCTs, I2 = 25%, fixed ef-
fect model, RR = 1.21, 95% CI (1.16, 1.25), P < 0.00001].
(As shown in Figure 4).Figure 2 Risk of bias.Sensitivity analysis
To confirm the stability of the result of the total clinical ef-
fective rate, we respectively removed the most and the least
weighted, and changed from fixed mode to random mode.
After removing the most weighted (Ma et al. [31]), the re-
sult was RR = 1.21 [95% CI (1.17, 1.26), P < 0.00001]. The
result of removing the least (Li et al. [15] and Wang et al.
[21]) was RR = 1.20 [95% CI (1.16, 1.25), P < 0.00001]. The
result of changing the mode was RR = 1.18 [95% CI (1.13,
1.23), P < 0.00001]. There was no obviously diversity, so
the degree of the sensitivity of the study was not high.
Neurological deficit score
There were seven trials mentioned neurological deficit
score [20,27,28,31-34]. Heterogeneity between studies was
large (P < 0.00001, I2 = 84 > 25%), we should use a random
effect model. The result showed that XST was more ef-
fective in reducing neurological deficit score. The statis-
tical difference between the two groups was significant
[MD = −4.35, 95% CI (−6.61, −2.08), P = 0.0002]. (Shown
in Figure 5).
Plasma viscosity
There were five trials mentioned the content of plasma
viscosity [15,17,23,28,31]. The result showed that XST
was more effective in reducing the content of plasma
viscosity. The statistical difference between two groups
was significant [5 RCTs, I2 = 77%, random effect model,
MD = −0.14, 95% CI (−0.21, −0.08), P < 0.00001]. (Shown
in Figure 6).
Adverse events
Five trials [19,21,32,33,37] reported 35 cases of AE.
None of participants who reported AE developed bleed-
ing or liver and kidney damage, and all participants with
AE recovered after symptomatic treatments. The occur-
rence of AE did not affect treatment process. There were
17 from 35 cases occurred in experimental group, which
were manifested as two cases of headache and nausea,
Figure 3 Funnel plot of the total effective rate of XST in the treatment of ACI. XST: Xuesaitong Injection; ACI: acute cerebral infarction.
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bleeding points in subcutaneous, four cases of dizziness,
palpitation, and five cases of flush. While 20 cases oc-
curred in control group, which were manifested as one
case of bleeding gums, one case of gastrointestinal
bleeding, three cases of nausea and vomiting, four cases
of dizziness and palpitation, five cases of bleeding points
in subcutaneous, and six cases of face red. Ten trials
clearly expressed that no ADRs/ADEs occurred in their
studies [20,21,25-28,30,31,34,35]. And the other eight
trials provided no information.
Discussion
Discussion on the systematic review
Following the systematic review, we can summarize that
XST as an adjuvant treatment for WM for ACI wasFigure 4 Meta-analysis of the total effective rate of XST in the treatmmore effective. It could increase the total clinical effect-
ive rate, decrease the degree of neurological deficit, and
reduce the content of plasma viscosity, which were con-
sistent with results of previous system reviews [11,12].
Compared with previously reported data, we were not
only adding more high-quality, small heterogeneous lit-
eratures, but also strictly controlling the course of dis-
ease and the medications of control group. Therefore,
the present systematic review was more scientific and
precise. But regarding outcome of neurological deficit
scores, Cai 2011 [32] reported large heterogeneity with
the other included studies, which may be related to less
effectiveness of Buflomedil Hydrochloride and low mo-
lecular heparin on improving neurological deficit. And
though the efficacy of XST for treating ACI is sure, its
safety remains to be further assessed. Accordingly, froment of ACI. XST: Xuesaitong Injection; ACI: acute cerebral infarction.
Figure 5 Meta-analysis of reducing neurological deficit scores of XST for testing ACI. XST: Xuesaitong Injection; ACI: acute cerebral infarction.
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using in clinical to form an integrative therapy.Recommendation on the efficacy evaluation of XST in the
treatment of ACI
A research from Asia Pacific Region found that significant
correlation exists between dyslipidemia and occurrence
of ischemic stroke. When the total cholesterol (TC) in-
creased by 1 mmol/L, the incidence of stroke will
increase by 25% [38-40]. Meanwhile, experiments dem-
onstrated that PNS, the main ingredient in XST, can sig-
nificantly reduce blood lipids and lipid peroxidation
products [41]. In the systematic review, only one study
[31] monitored the changes in TC was MD = −1.01[95%
CI (−1.41, −0.61), P < 0.00001)], which had significant
differences between two groups. Accordingly, depend-
ing on the GRADE methods, we propose that blood
lipids level should be used as one of the important indi-
cators for the evaluation of efficacy of XST for treating
ACI in the further clinical studies.
On the other hand, high C-reactive protein (Hs-CRP),
as a kind of acute phase proteins, may increase rapidly
when suffering various acute inflammations, tissue dam-
age, and other diseases. When patients improved, the con-
tent of Hs-CRP quickly returned to normal. Its increasing
has positive correlation with the degree of infection, and it
was with high sensitivity [42]. Accordingly, Hs-CRP can
be as an independent risk factor for cerebral infarction to
predict the severity of cerebral infarction and infarct size.Figure 6 Meta-analysis of reducing the content of plasma viscosity of XST fBut in the included studies, only 1 trail [35] compared the
changes in Hs-CRP, which result was MD = −6.62 [95% CI
(−8.29, −4.95), P < 0.00001]. In sum, depending on the
GRADE methods, we considered Hs-CRP can also serve
as one of important indicators in evaluation of efficacy of
ACI.XST’ADRs
In clinic, ADR of XST’s was reported in large quantity.
The common symptoms included headache, dry throat,
palpitation, pruritus, severe rash, and the severe even
have anaphylactic shock [43], which are generally in con-
sistent with the AEs that reported in our meta-analysis.
Although there were no serious ADRs, we could not
conclude on its safety yet. Therefore, special attention
should be paid to the observation of AE. The meta-
analysis showed that there were four studies [21,22,25,30],
in which their dose of XST exceeded 200 ~ 400 mg, and
such high dose may easily cause ADRs according to in-
struction manual. In addition, there were also one
study [44] showed that allergies occurrence time was
mostly to exceed 7d. It prompts that medical staffs
need to have a properly assessment on efficacy to avoid
overdose. Patients with allergic history have more
chance to suffer ADR, so the clinicians need to know
well the allergic history of patients. Furthermore, drug
combination is also a high risk for ADR occurrence; ac-
cordingly, it should reduce the quantity of drugs as few
as possible for combination use.or treating ACI. XST: Xuesaitong Injection; ACI: acute cerebral infarction.
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further clinical research
Although the systematic review showed that XST as ad-
juvant treatment for WM for ACI was effective, the
methodological quality of included studies was not ideal.
Only 6 studies described random allocation method, and
none of them described allocation concealment. Only
one study used single-blinding. All the RCTs had small
sample size. In the included studies, XST was products
from two manufacturers and the dosage of XST varied
a lot. In addition, the systematic review itself also has
some limitations. Since all trials were published in Chinese,
we could not exclude the potential publication bias. More
rigorously designed RCTs are needed to confirm the effect-
iveness of XST for ACI.
Conclusion
According to low quality evidences, XST as an adjuvant
treatment for conventional treatments for treating ACI
was beneficial comparing to conventional treatments
alone. Although the safety of XST requires further re-
search, it is worthy to be promoted using in clinical.
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